The contemporary health science research system, particularly in the frontier of nanobiotechnology, faces systematic bottlenecks caused by centralized structures. Despite the revolutionary potential of nanomaterials in areas like targeted drug delivery, biological interface regulation, and tissue engineering, their path from lab to application is fraught with obstacles:
Data Barriers and Value Monopolization
High-fidelity Real-World Health Data is siloed within academic institutions or corporate entities, leading to poor data circulation, validation difficulties, and severely limiting the speed of innovation.
Scientific Reproducibility Crisis
The lack of transparency in experimental processes and raw data makes independent verification of many cutting-edge research findings challenging, shaking the foundation of trust in scientific discovery.
AI Data Bottleneck
The efficacy of AI models in the health sector is severely limited by the availability of high-quality, diverse training data, constraining the ability to build accurate bio-intelligence models.
Participant Value Misalignment
Individuals who contribute critical physiological data are marginalized in the research value chain, unable to share in the revenues generated by scientific discoveries or access effective channels for research participation.
